Matches in SemOpenAlex for { <https://semopenalex.org/work/W1977643992> ?p ?o ?g. }
- W1977643992 endingPage "156" @default.
- W1977643992 startingPage "143" @default.
- W1977643992 abstract "Ovarian Sertoli cell tumors are rare, and their morphologic spectrum, behavior, and factors influencing the latter are not clearly established. They may be mimicked by many different tumors, some of them more frequent than Sertoli cell tumors; immunohistochemistry may aid in this differential, but its role has not been analyzed in a large series. We studied the clinicopathologic features of 54 Sertoli cell tumors, including the immunohistochemical profile of 23 of them. The patients, 6 of whom had Peutz-Jeghers syndrome, ranged from 2 to 76 years of age (mean, 30 years). Eleven patients had estrogenic and 4 had androgenic manifestations. The tumors ranged from 0.8 to 30 cm, with the majority being in the range of 4 to 12 cm. They were all unilateral, usually solid, and often yellow. The predominant microscopic pattern was tubular, seen, albeit often only focally, in all tumors; other patterns were cords or trabeculae (28), diffuse (21), pseudopapillary (4), retiform (3), islands or alveolar arrangements (3), and spindled (3). The tubules were solid or hollow with the former being somewhat more common. Delicate septa were occasionally seen and were conspicuous in areas of one tumor. The stroma was abundant in 15 tumors with marked sclerosis in 4. The cells usually had pale to occasionally densely eosinophilic cytoplasm, but 6 tumors were composed of cells with prominent foamy cytoplasm, falling in the category of “lipid-rich” Sertoli cell tumor, and one had cells with clear non-foamy cytoplasm. Forty-four tumors were stage I (42 of them were stage Ia and 2 were stage Ic), 1 was stage II, 3 were stage III, and 6 were not adequately staged. Follow-up was available for 27 patients with stage I tumors, and all were alive and well at last follow-up except for 2 patients with stage Ia and 1 with stage Ic disease. Those 3 patients had pelvic-abdominal recurrences 18, 36, and 9 months, respectively, after the initial diagnosis. Two of the three clinically malignant stage I tumors had moderate to severe cytologic atypia and brisk mitotic activity (>5 or more mitoses/10 high power fields [HPFs]), and one of these had tumor cell necrosis. Among the 10 clinically benign stage I tumors with more than 5 years of follow-up, only 3 had >5 mitoses/10 HPFs, but none had more than mild cytologic atypia and none had tumor cell necrosis. Two of the three patients with stage III disease had follow-up information and one was alive at 16 months and the second developed splenic metastases 2 years after the initial diagnosis. Two of the three stage III tumors had at least moderate cytologic atypia and brisk mitotic activity. Immunohistochemical stains showed positivity for AE1/3-Cam5.2 in 15 of 23 tumors; Epithelial membrane antigen (EMA) was negative in all the tumors. Inhibin was positive in 18 of 22 tumors, calretinin in 10 of 20, CD99 in 19 of 22, vimentin in 17 of 18, smooth muscle actin in 4 of 18, neuron specific enolase in 8 of 16, S-100 in 2 of 20, and chromogranin was negative in all 21 cases studied. Although Sertoli cell tumors usually have a distinctive tubular pattern that facilitates the diagnosis, other patterns may occasionally predominate, causing confusion with various other primary and metastatic ovarian tumors. EMA, inhibin, and chromogranin represent the most helpful triad of immunomarkers serving to exclude two common mimics of Sertoli cell tumors (endometrioid carcinoma [inhibin−; EMA+; chromogranin−] and carcinoid tumor [inhibin−; EMA+; chromogranin+]). Although CD99 and calretinin are often expressed in these tumors, they are much less specific and not as helpful in the differential diagnosis. Most Sertoli cell tumors are stage I, unilateral, cytologically bland, and clinically benign, but occasional examples are high stage, and about 11% of stage I tumors have worrisome histologic features that may portend an adverse outcome. The tumors typically occur in young females, sometimes children who typically present with sexual precocity, and occasional patients have Peutz-Jeghers syndrome." @default.
- W1977643992 created "2016-06-24" @default.
- W1977643992 creator A5046207285 @default.
- W1977643992 creator A5052359409 @default.
- W1977643992 creator A5069885975 @default.
- W1977643992 date "2005-02-01" @default.
- W1977643992 modified "2023-10-17" @default.
- W1977643992 title "Sertoli Cell Tumors of the Ovary" @default.
- W1977643992 cites W1561703067 @default.
- W1977643992 cites W1964071862 @default.
- W1977643992 cites W1965503173 @default.
- W1977643992 cites W1966596967 @default.
- W1977643992 cites W1968012244 @default.
- W1977643992 cites W1968243006 @default.
- W1977643992 cites W1968312126 @default.
- W1977643992 cites W1970023355 @default.
- W1977643992 cites W1976973591 @default.
- W1977643992 cites W1978957756 @default.
- W1977643992 cites W1979053455 @default.
- W1977643992 cites W1981094336 @default.
- W1977643992 cites W1984385354 @default.
- W1977643992 cites W1986394571 @default.
- W1977643992 cites W1986891431 @default.
- W1977643992 cites W1994150533 @default.
- W1977643992 cites W2002671913 @default.
- W1977643992 cites W2003945247 @default.
- W1977643992 cites W2006192676 @default.
- W1977643992 cites W2021312580 @default.
- W1977643992 cites W2023626813 @default.
- W1977643992 cites W2028861374 @default.
- W1977643992 cites W2033622292 @default.
- W1977643992 cites W2043467897 @default.
- W1977643992 cites W2045599880 @default.
- W1977643992 cites W2047529900 @default.
- W1977643992 cites W2049440768 @default.
- W1977643992 cites W2049954116 @default.
- W1977643992 cites W2057063971 @default.
- W1977643992 cites W2057637200 @default.
- W1977643992 cites W2068223487 @default.
- W1977643992 cites W2069368085 @default.
- W1977643992 cites W2072068089 @default.
- W1977643992 cites W2072783299 @default.
- W1977643992 cites W2076706610 @default.
- W1977643992 cites W2077881076 @default.
- W1977643992 cites W2079140480 @default.
- W1977643992 cites W2081377036 @default.
- W1977643992 cites W2081773086 @default.
- W1977643992 cites W2082604710 @default.
- W1977643992 cites W2086343491 @default.
- W1977643992 cites W2087970560 @default.
- W1977643992 cites W2090583989 @default.
- W1977643992 cites W2091970582 @default.
- W1977643992 cites W2095198736 @default.
- W1977643992 cites W2132847585 @default.
- W1977643992 cites W2142135448 @default.
- W1977643992 cites W2144717315 @default.
- W1977643992 cites W2151323892 @default.
- W1977643992 cites W2162931662 @default.
- W1977643992 cites W2191062305 @default.
- W1977643992 cites W2332259966 @default.
- W1977643992 cites W4246039434 @default.
- W1977643992 cites W4380763390 @default.
- W1977643992 doi "https://doi.org/10.1097/01.pas.0000149692.21205.9c" @default.
- W1977643992 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15644771" @default.
- W1977643992 hasPublicationYear "2005" @default.
- W1977643992 type Work @default.
- W1977643992 sameAs 1977643992 @default.
- W1977643992 citedByCount "157" @default.
- W1977643992 countsByYear W19776439922012 @default.
- W1977643992 countsByYear W19776439922013 @default.
- W1977643992 countsByYear W19776439922014 @default.
- W1977643992 countsByYear W19776439922015 @default.
- W1977643992 countsByYear W19776439922016 @default.
- W1977643992 countsByYear W19776439922017 @default.
- W1977643992 countsByYear W19776439922018 @default.
- W1977643992 countsByYear W19776439922019 @default.
- W1977643992 countsByYear W19776439922020 @default.
- W1977643992 countsByYear W19776439922021 @default.
- W1977643992 countsByYear W19776439922022 @default.
- W1977643992 countsByYear W19776439922023 @default.
- W1977643992 crossrefType "journal-article" @default.
- W1977643992 hasAuthorship W1977643992A5046207285 @default.
- W1977643992 hasAuthorship W1977643992A5052359409 @default.
- W1977643992 hasAuthorship W1977643992A5069885975 @default.
- W1977643992 hasConcept C123765429 @default.
- W1977643992 hasConcept C134018914 @default.
- W1977643992 hasConcept C142724271 @default.
- W1977643992 hasConcept C190062978 @default.
- W1977643992 hasConcept C204232928 @default.
- W1977643992 hasConcept C2778324911 @default.
- W1977643992 hasConcept C2779758542 @default.
- W1977643992 hasConcept C2781068068 @default.
- W1977643992 hasConcept C52124034 @default.
- W1977643992 hasConcept C71924100 @default.
- W1977643992 hasConcept C86803240 @default.
- W1977643992 hasConcept C95444343 @default.
- W1977643992 hasConceptScore W1977643992C123765429 @default.
- W1977643992 hasConceptScore W1977643992C134018914 @default.